M&A / Deals Boehringer signs AI drug discovery deal with Owkin PharmaphorumBoehringer Ingelheim has joined Sanofi and AstraZeneca in signing up to deploy Owkin's AI platform K Pro in its drug discovery operations.Read full story pharminent September 3, 2026 (Last updated: September 3, 2026) Pharmaphorum Boehringer Ingelheim has joined Sanofi and AstraZeneca in signing up to deploy Owkin’s AI platform K Pro in its drug discovery operations. Read full story Post navigation Previous: Novartis signs $3.2bn drug delivery deal with AlteogenNext: Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial–again Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026